Valbenazine

Generic Name
Valbenazine
Brand Names
Ingrezza
Drug Type
Small Molecule
Chemical Formula
C24H38N2O4
CAS Number
1025504-45-3
Unique Ingredient Identifier
54K37P50KH
Background

Valbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of tetrabenazin...

Indication

Valbenazine is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.

Associated Conditions
Chorea, Tardive Dyskinesia (TD)
Associated Therapies
-
Clinical Trials
Related News

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Phase 3
Conditions
Chorea, Huntington
Interventions
Drug: Valbenazine
First Posted Date
2024-03-15
Last Posted Date
2024-05-16
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
7
Registration Number
NCT06312189
Locations
🇨🇦

Neurocrine Clinical Site, Toronto, Ontario, Canada

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

First Posted Date
2023-05-16
Last Posted Date
2024-07-12
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
59
Registration Number
NCT05859698
Locations
🇺🇸

Neurocrine Clinical Site, Houston, Texas, United States

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Phase 3
Terminated
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: Valbenazine
First Posted Date
2022-12-16
Last Posted Date
2024-11-11
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
8
Registration Number
NCT05654870
Locations
🇺🇸

Neurocrine Clinical Site, Atlanta, Georgia, United States

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Phase 3
Recruiting
Conditions
Dyskinesia
Cerebral Palsy
Interventions
Drug: Placebo
Drug: Valbenazine
First Posted Date
2022-01-25
Last Posted Date
2024-06-24
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
80
Registration Number
NCT05206513
Locations
🇪🇸

Neurocrine Clinical Site, San Sebastián, Spain

🇦🇷

Neurocrine Clincial Site, Ciudad Autónoma de Buenos Aires, Argentina

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Phase 3
Recruiting
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: Valbenazine
First Posted Date
2021-11-05
Last Posted Date
2024-06-21
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
400
Registration Number
NCT05110157
Locations
🇷🇸

Neurocrine Clinical Site, Vršac, Serbia

🇺🇸

Neurocrine Clinical Sites, Glen Oaks, New York, United States

🇷🇸

Neurocrine Clinical Site 1, Kragujevac, Serbia

and more 5 locations

Psychological Adjustment to Tardive Dyskinesia

Phase 1
Recruiting
Conditions
Tardive Dyskinesia
Interventions
Drug: Valbenazine
First Posted Date
2021-09-22
Last Posted Date
2024-11-26
Lead Sponsor
Yale University
Target Recruit Count
15
Registration Number
NCT05053321
Locations
🇺🇸

Yale Church Street Research Unit., New Haven, Connecticut, United States

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Phase 3
Active, not recruiting
Conditions
Chorea, Huntington
Interventions
Drug: Valbenazine
First Posted Date
2020-05-22
Last Posted Date
2023-12-29
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
154
Registration Number
NCT04400331
Locations
🇨🇦

Neurocrine Clinical Site, Toronto, Ontario, Canada

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Phase 3
Completed
Conditions
Chorea, Huntington
Interventions
Drug: Valbenazine
Drug: Placebo
First Posted Date
2019-09-25
Last Posted Date
2023-10-11
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
128
Registration Number
NCT04102579
Locations
🇨🇦

Neurocrine Clinical Site, Toronto, Ontario, Canada

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

First Posted Date
2019-03-27
Last Posted Date
2021-04-20
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
135
Registration Number
NCT03891862
Locations
🇵🇷

Neurocrine Clinical Site, San Juan, Puerto Rico

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

First Posted Date
2018-10-09
Last Posted Date
2020-06-04
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
89
Registration Number
NCT03698331
Locations
🇵🇷

Neurocrine Clinical Site, San Juan, Puerto Rico

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy